RE:RE:2023.2023 sale will be down compares to 2022 and all cash needed for the AV pill trial and scale up will bring the liquidity much lower at the end of the year so the share price has adjusted for this new reality and the stock should trade in the $0.40 rang for the rest of the year UNLESS pre-clinicla trial demonstrates significant results for fibrosis and possibly attract big players this is the only catalyst i can see now.
But it won't be financially possible to conduct the AV trial , the scale up and start a Phase 1a cliniclal trial for fibrosis and this is why no explanation has been given for the delay